ALVAC-HIV vCP 205 live recombinant canarypox vector vaccine: Update

The trial will involve 420 adults at either high or low risk for HIV infection divided into

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE